Viamet Postpones $86 Million IPO

Published: May 12, 2016

Viamet Pharmaceuticals Holdings, a biotech developing small molecule metalloenzyme inhibitors to treat fungal diseases, postponed its IPO on Wednesday. It had filed to raise $86 million by offering 5.7 million shares at a price range of $14 to $16.

The Durham, NC-based company was founded in 2004 and booked $1 million in sales for the 12 months ended March 31, 2016. It had planned to list on the Nasdaq under the symbol VMET. Morgan Stanley and Goldman Sachs were set to be the joint bookrunners on the deal.

Back to news